Mydecine Innovations Group Provides Update on European Operations Company Appoints Former Novartis Norway CEO as President of European Operations, and Partners with Dr. David Erritzoe in the set up of a novel collaborative psychopharmacology/psychedelic research clinic between Imperial College London and a major mental health NHS Trust in London Mydecine Innovations Group Inc.
DENVER, March 16, 2021 (GLOBE NEWSWIRE)
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has appointed Michel Rudolphie, former CEO and President of Make-A-Wish International and former Novartis Norway CEO, as President of the Company’s European Operations. In addition to adding new leadership, the Company also announces that it has partner
Mydecine Innovations Group Provides Update on European Operations biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Pipeline NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
DENVER, Feb. 24, 2021 (GLOBE NEWSWIRE) Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced an exclusive partnership with Applied Pharmaceutical Innovation (API) at the University of Alberta, as well as expanded capabilities that enables support of multiple drug development and clinical trial programs simultaneously.
“With our expanded relationship with API, we can now synthesise multiple molecules concurrently as well as run research and development and pre-clinicals on site,” said Rob Roscow, Chief Scientific Officer and Co-founder of Mydecine. “We now have the ability to accelerate both natural product research and novel drug design, specific
Mydecine Innovations Group, Inc., is pleased to announce that its subsidiary Mindleap Health a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office and the Canadian Intellectual Property Office. “As our company continues to innovate …
Mydecine Innovations Group, Inc., ( CSE:MYCO ) ( OTC:MYCOF ) ( FSE:0NFA ) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office (USPTO) and the Canadian Intellectual Property Office.
Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange globalbankingandfinance.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalbankingandfinance.com Daily Mail and Mail on Sunday newspapers.